Minocycline in Major Depressive Disorder: And overview with considerations on treatment-resistance and comparisons with other psychiatric disorders
Maria Antonietta Nettis
Abstract
Evidence on the link between the immune system and Major Depressive Disorder (MDD) has led to explore antidepressant properties of anti-inflammatory drugs. Among these, minocycline has been identified as a potential novel treatment for MDD, in particular for treatment-resistant depression. The aim of the current paper is to review current pre-clinical and clinical evidence on the antidepressant efficacy of minocycline. The review includes considerations on the role of both peripheral and central inflammation in the response to minocycline and comparisons of minocycline efficacy across different psychiatric disorders (i.e., unipolar depression, bipolar depression, and schizophrenia).
Topics & Concepts
MinocyclineAntidepressantMajor depressive disorderDepression (economics)Schizophrenia (object-oriented programming)PsychiatryBipolar disorderMedicineTreatment-resistant depressionPsychologyClinical psychologyCognitionAnxietyAntibioticsEconomicsMacroeconomicsBiologyMicrobiologyTryptophan and brain disordersStress Responses and CortisolNeuroinflammation and Neurodegeneration Mechanisms